Hybridoma Technologies for Antibody Production

Abstract

Hybridoma technology features effective usage of innate functions of both immune cells and cancers, allowing production of hybridoma cells, which continuously generate monoclonal antibodies specific to antigens of interest. For standard generation of hybridoma cells, B lymphocytes must be somatically fused with myeloma cells using various technologies. However, the methods generally do not necessarily result in selective fusion of target B lymphocytes with myeloma cells. To overcome this problem, we have developed a new hybridoma technology that involves preselection of B lymphocytes with target antigens based on immunoglobulin receptors and selective fusion of B cell-myeloma cell complexes with electrical pulses. The advanced methodology, termed B-cell targeting, multitargeting and stereospecific targeting, may be applicable to simultaneous production of monoclonal antibodies, selective production of stereospecific monoclonal antibodies, and also to efficient generation of human monoclonal antibodies for clinical purposes.

Antibody Engineering for Pursuing a Healthier Future

“…The technology remains a feasible method for laboratories that implement basic cell biological research. Hybridoma technology is a comparatively simple procedure with minimal cost for the steady production of native whole immunoglobulins (Tomita and Tsumoto, 2011). Nevertheless, this technology has various limitations such as antibodies produced by the hybridoma technique are strictly murine proteins that limits their therapeutic use in humans.…”

Identification of HBsAg-specific antibodies from a mammalian cell displayed full-length human antibody library of healthy immunized donor

“…DISCUSSION A key step in the development of antibody therapy is the identification of target antigen-specific antibodies. Hybridoma [25][26][27] technology is commonly used in screening and selecting these antibodies. In most situations, they are nonhuman antibodies, which need to be humanized for further development as therapeutics.…”

Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies

“…In the mid-1970s, hybridoma technology was invented for production of mouse monoclonal antibodies with defined antigen specificities and neutralization activity for application in clinical therapies (Kelso et al, 2016;Hugwil, 2013;Tomita and Tsumoto, 2011;Martin-Lopez et al, 2007;Hencsey et al, 1996;Honda et al, 1990;Köhler and Milstein, 1975). Hybridomas can be generated by effective fusion of B cells and partner cells followed by screening of individual antibody producing cells.…”